Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma.
Naita Maren WirsikMingyi ChenLiping HeUraz YasarJustus GaukelAlexander QuaasHenrik NienhüserElla LeugnerShuai YuanNikolai SchleussnerJin-On JungJadie Sue PlückerMartin SchneiderThomas SchmidtPublished in: Cancer medicine (2024)
Our findings demonstrate the potential value of MerTK as a prognostic biomarker for gastric adenocarcinoma. Targeting MerTK may become a new treatment option, especially for patients with advanced tumors, and may overcome resistance to established chemotherapies.